Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine- 3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human

Drug Metabolism and Disposition

Volumn 35, Issue 11, 2007, Pages 2111-2118

  Kalgutkar, Amit S ^a   Feng, Bo ^a   Nguyen, Hang T ^a   Frederick, Kosea S ^a   Campbell, Scott D ^a   Hatch, Heather L ^a   Bi, Yi An ^a   Kazolias, Diana C ^a   Davidson, Ralph E ^a   Mireles, Rouchelle J ^a   Duignan, David B ^a   Choo, Edna F ^a,b   Zhao, Sabrina X ^a  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [[[2 (BENZO[1,3]DIOXOL 5 YLOXY) PYRIDINE 3 CARBONYL] AMINO] METHYL] 3 FLUORO PHENOXY] PROPIONIC ACID; BREAST CANCER RESISTANCE PROTEIN; CP 671305; CYCLOSPORIN A; MULTIDRUG RESISTANCE PROTEIN 1; PHOSPHODIESTERASE IV INHIBITOR; PROPIONIC ACID; RIFAMPICIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HEPATOCYTES; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MOLECULAR STRUCTURE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; PHOSPHODIESTERASE INHIBITORS; PROPIONIC ACIDS; PYRIDINES; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; TRANSFECTION;

RATTUS;

EID: 35548989313     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016162     Document Type: Article

References (41)

1. Bi YA, Kazolias D, and Duignan DB (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34:1658-1665.
2. Büchler M, König J, Brom M, Kartenbeck J, Spring H, Horie T, and Keppler D (1996) cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 271:15091-15098.
3. Campbell SD, de Morais SM, and Xu JJ (2004) Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179-187.
4. Chandra P and Brouwer KL (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm Res 21:719-735.
5. Chen WY, Bailey EC, McCune SL, Dong JY, and Townes TM (1997) Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci U S A 94:5798-5803.
6. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
7. Dresser GK, Kim RB, and Bailey DG (2005) Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 77:170-177.
8. Eckhardt U, Schroeder A, Stieger B, Hochli M, Landmann L, Tynes R, Meier PJ, and Hagenbuch, B (1999) Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am J Physiol 276:G1037-G1042.
9. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, and Stieger B (2000) Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32:82-86.
10. Ghanem CI, Ruiz ML, Villanueva SS, Luquita MG, Catania VA, Jones B, Bengochea LA, Vore M, and Mottino AD (2005) Shift from biliary to urinary elimination of acetaminophen-glucuronide in acetaminophen-pretreated rats. J Pharmacol Exp Ther 315:987-995.
11. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, and Mao Q (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374-383.
12. Hamman MA, Bruce MA, Haehner-Daniels BD, and Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69:114-121.
13. Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, and van Gelder T (2005) Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 5:987-994.
14. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807.
15. Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T, and Sugiyama Y (1998) Hepatic expression of multidrug resistance-associated protein-like proteins maintained in Eisai hyperbilirubinemic rats. Mol Pharmacol 53:1068-1075.
16. Houslay MD, Schafer P, and Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503-1519.
17. Johnson BM, Zhang P, Schuetz JD, and Brouwer KL (2006) Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab Dispos 34:556-562.
18. Kalgutkar AS, Choo E, Taylor TJ, and Marfat A (2004) Disposition of CP-671,305, a selective phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica 34:755-770.
19. Kamath AV, Yao M, Zhang Y, and Chong S (2005) Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 94:233-239.
20. Kim RB (2006) Transporters and drug discovery: why, when and how. Mol Pharm 3:26-32.
21. Kivistö KT, Grisk O, Hofmann U, Meissner K, Moritz KU, Ritter C, Arnold KA, Lutjoohann D, von Bergmann K, Kloting I, et al. (2005) Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. Drug Metab Dispos 33:1593-1596.
22. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, and Hirano T (2004) Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 309:1029-1035.
23. König J, Cui Y, Nies AT, and Keppler D (2000a) A novel human organic anion transporting polypeptide localized to the basolateral hepatocytes membrane. Am J Physiol Gastrointest Liver Physiol 278:G156-G164.
24. König J, Cui Y, Nies AT, and Keppler D (2000b) Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 275:23161-23168.
25. Lau YY, Okochi H, Huang Y, and Benet LZ (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771.
26. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, and Pang KS (2006) Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther 318:395-402.
27. Liu X, Chism JP, LeCluyse EL, Brouwer KR, and Brouwer KL (1999a) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637-644.
28. Liu X, LeCluyse EL, Brouwer KR, Gan L-S, Lemasters JJ, Stieger B, Meier PJ, and Brouwer KL (1999b) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 277:G12-G21.
29. Markham A and Wagstaff AJ (1998) Fexofenadine. Drugs 55:269-276.
30. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, and Abe T (2004) The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 19:171-179.
31. 4, and taurocholate. Biochem Biophys Res Commun 275:831-838.
32. Noé B, Hagenbuch B, Stieger B, and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci U S A 94:10346-10350.
33. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, and Tsuji A (2006) Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34:1423-1431.
34. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, and Sugiyama Y (2005) Contribution of OATP family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477-1481.
35. Shitara Y, Hirano M, Adachi Y, Itoh T, Sato H, and Sugiyama Y (2004) In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. Drug Metab Dispos 32:1468-1475.
36. Shitara Y, Horie T, and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
37. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, and Sugiyama Y (2002) Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res 19:147-153.
38. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, and Tsuji A (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251-260.
39. Treiber A, Schneiter R, Häusler S, and Stieger B (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400-1407.
40. Xiao Y, Davidson R, Smith A, Pereira D, Zhao S, Soglia J, Gebhard D, de Morais S, and Duignan DB (2006) A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm 3:45-54.
41. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, and Ware JA (2006) Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3:55-61.